Menopause, long an underserved health topic, is moving out of the shadows and going mainstream – and Australia’s aesthetic practitioners have an important role to play.

Menopause has long been a taboo subject, often whispered about but rarely openly discussed; a biological stage experienced universally by middle-aged women, yet historically marginalised in both medical research and product development. For too long, menopause has been ignored and symptoms diminished.

Despite the public health importance of menopause, not to mention the economic and social cost, there are important gaps in our knowledge of the effects of menopause on numerous systems of the body.

However, the tide is turning. Menopause has become one of the most talked about health topics and is now being recognised as an urgent matter of public policy. In Australia, the recent Senate Inquiry into Issues related to menopause and perimenopause is setting the stage for a new era of care and understanding for women’s health.

For aesthetic medical practitioners, this overlooked corner of women’s health offers a ripe opportunity to support patients through menopause. As the aesthetics industry continues its shift from simply correcting the signs of ageing to seeking to address ageing at its source, aesthetic practitioners are well placed to play a pivotal role in a perimenopausal or menopausal woman’s care – going beyond skin-deep treatments to address some of the broader impacts of menopause.

Menopause: more than hot flashes

Menopause, a natural biological process, marks the end of a woman’s reproductive years. It is a transitional phase that typically occurs between the ages of 45 and 55, signalling the cessation of menstrual cycles.

During menopause, the ovaries gradually diminish their production of oestrogen and progesterone, the primary female hormones responsible for regulating various bodily functions.

This hormonal shift can trigger a wide range of symptoms, including hot flushes, night sweats, brain fog, mood changes, sleep disturbances, incontinence, vaginal atrophy, physical changes such as weight gain and body fat composition (especially central adiposity), and joint pain and muscle loss.

The menopausal transition extends well beyond these more commonly associated symptoms. Other symptoms include: heart palpitations; menorrhagia; genitourinary syndrome of menopause; oestrogen-deficient skin; dry eye syndrome; neuropathic pain or paraesthesia; snoring; tinnitus; hair loss; allergies; and temporomandibular disorder (TMD).

Menopause is not merely a change in hormones that needs temporary mollification – it is a complex interplay of a variety of factors affecting multiple systems of the female body.

Oestrogen, in particular, has far-reaching effects on the body. It influences how the body uses calcium, maintains cholesterol levels in the blood, and protects against cardiovascular diseases. The decline in oestrogen levels and its association with accelerated bone loss and decreased bone mineral density are well established. It has also been linked to increased risk of cardiovascular disease, diabetes and some cancers.1

Genitourinary syndrome of menopause (GSM) affects 45 to 63 percent of postmenopausal women in Western populations.2 It encompasses a range of symptoms affecting the genital and urinary systems and is characterised by vaginal dryness, irritation, burning and itching, decreased lubrication and discomfort during intercourse. Urinary symptoms, including urgency, dysuria and recurrent urinary tract infections, are also common.

Due to changing sex hormones in the brain, perimenopause symptoms can also be neuropsychiatric and include such symptoms as irritability, low mood, intrusive thoughts,
brain fog, fatigue, loss of joy and insomnia. As much as 45 to 68 percent of perimenopausal women develop depressive symptoms.3

Anxiety is another common psychological effect. There are few studies about anxiety and perimenopause, however some evidence4 finds the incidence of anxiety disorder in menopausal women is as high as 25 percent and its severity is related to the severity of the menopausal syndrome. Changes in physical health, such as thyroid issues or sleep disturbances due to night sweats, can also contribute to anxiety and depression.

HRT: Exploding the oestrogen myth

‘There are 3.28 million Australian women aged 40-59 years old today going through varying stages of perimenopause and menopause,’ says Dr Liz Golez, GP-obstetrician and principal cosmetic doctor at Lift Aesthetics in Sydney. ‘Twenty-eight percent of women will experience severe vasomotor symptoms such as hot flushes (the hallmark of menopausal transition/perimenopause and early postmenopause). Despite available safe treatments (menopausal hormonal therapy (MHT) or non- hormonal therapies), more than 85% of Australian women bothered by these symptoms fail to receive approved therapy.

‘Genitourinary syndrome of menopause (vaginal dryness, vulvovaginal atrophy, itching, laxity, and incontinence) affects 50% of post-menopausal women but only 7% get prescribed with oestrogen therapy.’

MHT, then known as hormone replacement therapy (HRT), was highly prevalent in the 1990s in the US, but a single flawed study in 2002 reporting elevated health risks drastically altered its course.

‘I think there are a couple of reasons we have got menopause so wrong,’ says Dr Ginni Mansberg, an Australian GP and television presenter with a special interest in menopause and women’s health. ‘For years menopause was perhaps overmanaged, at least in the US. Premarin – an old-school synthetic form of oestrogen – was the top- selling pharmaceutical in the US in the early 1990s! But a few things happened.

‘First, the 2002 Women’s Health Initiative (WHI) study was reported as showing a link between HRT and breast cancer. Sure, it did – for women with an average age of 63 when starting synthetic high-dose HRT. The quantum of risk? For every 10,000 women on a placebo, we saw 30 breast cancers, but we saw 38 in the takers of HRT. Not a big increase. If you took the group of women who started taking HRT before age 60, there was no increase in risk. But the finer details were just missed by reporters.

‘After this, journalist Barbara Seaman wrote The Greatest Experiment Ever Performed on Women: Exploding the Estrogen Myth. The prevailing view became that taking HRT is deadly and basically an indulgent beauty treatment, that to ask for it showed weakness. Women shut up. Doctors stopped learning about menopause and the whole thing fell under the cone of silence.’

Dr Judy Craig, medical director of Natural Looks Cosmetic Medicine in Perth, says this narrative continues to be perpetuated. ‘A large barrier to positive action to address the medical and economic consequences of oestrogen deficiency (menopause) is a reluctance of organisations, including medical advisory bodies and governments, to embrace the latest research data showing thepositive health benefits of MHT and new evidence in breast cancer risk with body-identical MHT over synthetic MHT,’ she says.

‘Until health professionals advising government accept data from recent studies that show that body-identical oestrogen alone reduces the risk of breast cancer, and combined with micronised progesterone has not been shown to increase the risk of breast cancer5, changes in the management of menopause will not occur, or will change very slowly as many doctors are reluctant to go against the recommendation of advisory bodies. Greater confidence in the safety of body-identical MHT will result from further studies if they confirm the findings in the study by Emilie Cordina-Duverger et al5.

‘Globally, MHT prescribing in women aged 45 to 64 averages only 5%, and in Australia, 14%. This is despite studies showing reductions in all-cause mortality and an increase in longevity for women on body-identical MHT.’

Dr Craig argues that only by improving awareness, increasing research funding and fostering open dialogue can we begin to address the gaps in menopause care and support. This shift is crucial not only for improving the quality of life for women but also acknowledging and addressing the broader economic and social costs associated with menopause.

‘For change to occur, I believe that we need more women in all aspects of management, government, research and education at an executive level and we need them to be informed on the issues facing menopausal women and be aware of the latest research and economic impact,’ she stresses. ‘Increasing public and government awareness may in time precipitate change.’

Menopause consultation

Medical misogyny & paucity of research

Appropriate care for menopausal women has been thwarted by various barriers, one of which is a paucity of research. Menopause has long been marginalised as a health concern, deemed insignificant when compared to other medical conditions. It can be argued this stems from societal tendencies to undervalue women’s health issues, particularly those related to ageing.

‘Historically, women’s health issues have been neglected, trivialised and underfunded,’ says Dr Craig. ‘While many are familiar with how the concept of “hysteria” was used to dismiss and pathologise women’s challenges in the 18th and 19th centuries, they may be shocked to realise that before 1993 women were rarely included in clinical trials, leading to a lack of proven data on the effects of many drugs and treatments on women.

‘In addition, there has been little investment in research into women’s health. A report from McKinsey and company stated that approximately one percent of healthcare research and innovation (2021) was invested in female-specific conditions beyond oncology.

‘This neglect of women’s health research has also led to an ignorance of the prevalence of the medical, psychological and economic impact of menopause on women. In 2017 a review of the literature found that there were few studies assessing the impact of menopause transition on women’s careers. Studies addressing the economic impact of menopause transition have predominantly been published since 2022.’

According to a 2023 perspective in Nature Ageing6, less than one percent of published studies of the biology of ageing considered menopause. This gap in research must certainly translate to gaps in women’s health care.

‘When we look at age-related diseases, over 75 percent of them are likely influenced by menopause in one way or another. But the great majority of preclinical biology research studies in ageing fail to consider menopause in their experimental setup,’ lead author Fabrisia Ambrosio, PhD, shared in an interview with Harvard Medical Magazine.7

‘Menopause is inextricably intertwined with ageing in female individuals. On average, females will live about a third of their lives postmenopausal. We lack data to understand how menopause affects ageing and how it might contribute to disease or age-related declines. In preclinical models, it’s something that we just haven’t effectively addressed, and so we haven’t been able to study it well.

‘The science has so much catching up to do. Hundreds of years of research studies have been dominated by male animal models and male humans.’

In February 2023 the Australian Government established a National Women’s Health Advisory Council to examine the systemic issues impacting gender inequities in health outcomes and improve Australia’s health system for women and girls.

The council will provide strategic advice to the government after looking at the healthcare offered in areas such as menstruation, reproductive healthcare, menopause, medical consent and pain management.

Dr Sarah White, CEO of Jean Hailes for Women’s Health and a member of the Women’s Health Council, wants the agency to address gendered gaps in research. ‘So much medical research has studied males and then generalised those findings to females,’ she told abc.net.au.8

‘The Therapeutic Goods Administration (TGA) should not approve medicines unless there is sufficient data around quality, safety and efficacy for males and females separately,’ Dr White says.

‘As a society, none of us seems to have a problem understanding that we need paediatric research and children’s hospitals. We intuitively understand that small boys are not the same as men, but for some reason, we treat women as if they’re small men.

‘We also need different treatment guidelines and public awareness campaigns. If you look at something like menopause, it affects 50 percent of the population and, of those, 10 percent will have symptoms that really impact their ability to work, live, study and play. But we still don’t have anywhere near enough research on it.

‘We need to make sure there is equality of funding for conditions like endometriosis and menopause, and perhaps even more funding, to make up for injustices in the past.’ Tricia Currie, head of the Victorian Women’s Health Council and CEO of Women’s Health Loddon Mallee, told abc.net.au8 that women’s voices are not being heard in the healthcare system.

‘When we do our work as women’s health services and ask women what’s missing from medical care, time and again they say ‘we’re not being heard’. They might be speaking, they might be telling their story, but they’re not actually being heard.

‘There’s unconscious bias within the health care system, which is why it is important that we have structures around decision-makers that ensure governments are hearing from women, and diverse women, about not only what the issues are but what some of the potential solutions are.’

Knowledge gap amongst HCPs

There remains a gap in knowledge of the complexities of menopause amongst healthcare practitioners, resulting in inadequate health care and/or a deficiency of care options for those who are menopausal or in the perimenopausal stage.

Dr Liz Golez says the menopause ‘knowledge gap’ started 20 years ago. ‘Research shows that GPs, gynaecologists and pharmacists mostly lack the skills and confidence in managing menopause,’ she says. ‘The medical knowledge gap began 20 years ago when the conflicting WHI study spread false and frightening information about HRT.

‘The knowledge gap trickles down to the consumer, the women who have been failed by the medical system, since they were never empowered by their women’s health provider to watch out for these symptoms of menopause or get started on MHT or non-hormonal treatments in a timely manner.’

‘We certainly have to acknowledge that treatment in this space is suboptimal,’ Dr Ginni Mansberg agrees. ‘It is not taught in medical school or even as part of GP, endocrinology or gynaecology training. For your doctor to be ‘up to date’, they need to invest a lot of time and money to join societies and upskill their knowledge on their own. That’s not to say that the experiences of serious medical gaslighting that I hear about every single day are okay; it’s just awful.’

In a 2023 perspective in the Medical Journal of Australia, the authors write that lack of clinician knowledge, poor access to services, negative attitudes and lagging research have led to substandard menopause‐related health care.9 ‘Irrespective of symptoms, menopause causes silent biological changes that may increase women’s risks of cardiovascular disease, diabetes, osteoporosis and some cancers. Consequently, it should be expected that health care providers, especially general practitioners, are equipped to provide evidence‐based menopause advice to the 3.28 million Australian women aged 40–59 years. Sadly, this is not the case.

The authors argue that first-line management of menopause‐ associated issues should be occurring at the level of primary care, yet GPs and specialists are not equipped to confidently manage menopause and frequently recommend unproven, and often ineffective, complementary therapies before prescribing MHT or effective non‐hormonal therapy.

‘Contributing to this health care knowledge gap are two decades of widespread dissemination of conflicting, and often frightening, information about menopause treatment, and omission of menopause from most undergraduate and post‐graduate medical and allied health training. Thus, state‐of‐the‐art menopause care is not available to most Australian women,’ the authors state.

Menopause and Public Policy

Governments across the world are beginning to recognise menopause as the urgent matter of public policy it is. The National Institute on Aging in the USA and the National Health Service (NHS) in the UK have introduced guidelines and resources specifically targeted at menopausal care.

In the UK, where menopausal women are believed to be the fastest-growing workplace demographic, more than 500 workplaces have been certified as ‘menopause-friendly’. Anti- discrimination laws that include menopausal status have also been bolstered, with employers now legally obliged to make ‘reasonable adjustments’ for women going through menopause.

In November 2023 the US government created a Women’s Health Research Initiative to determine gaps and infuse new funding, the first tranche of which is US$100 million. Further, a new bill, the Menopause Research and Equity Act of 2023, has been presented to Congress to ensure commitment to ongoing research related to menopause, perimenopause or mid-life women’s health.

In Australia, there is a push for menopause to be more widely recognised as a significant health issue – and the recent Senate Inquiry suggests the issue of menopause is finally beginning to receive some attention.

‘As the awareness of the economic impact is very recent, it will take time to translate into affirmative action in many nations,’ says Dr Judy Craig. ‘I believe that the UK has led the way in this regard. The UK government passed the Menopause and the Equality Act in 2010, which details how workers may be impacted by menopause and outlines the legal obligations that employers have under the Act. On 6 March 2023 the Minister appointed Helen Tomlinson as the Government’s DWP Menopause Employment Champion. Tomlinson’s aim is to educate women and encourage employers to sign the Menopause pledge. This is an important step in the process of raising awareness and supporting women in the workforce whilst they navigate the transition to menopause and then manage post- menopausal changes for life.

‘In contrast, the Australian government initiative, announced by the Albanese government, is to invest in digital tools to improve access to quality care for women. I could not find any workplace affirmative action.

‘A colleague of mine shared the experience of a woman she was treating for severe incontinence requiring full pads and frequent trips to the bathroom to change. She was perceived as inefficient by her supervisor and lacking dedication to her job and was fired. As a result of this, she became homeless. Her homelessness resulted from a combination of embarrassment, preventing her from seeking help earlier, little or no government funding to provide treatment for women with incontinence, and lack of workplace understanding and support. Employer awareness of menopausal issues and a supportive work environment could have resulted in help, rather than unemployment and homelessness.’

“MANY WOMEN FEEL LET DOWN BY THEIR GPS WHEN IT COMES TO MENOPAUSE, AND AESTHETIC CLINICS ARE INCREASINGLY BECOMING THE PLACE THEY TURN TO.” – Charlotte Body, Founder of Menopause in Aesthetics, UK

The role of Aesthetic Clinics

‘Menopause care aligns seamlessly with the mission of aesthetics and anti-ageing clinics, which focus on addressing the signs and effects of ageing,’ says Dr Judy Craig. ‘The hormonal changes associated with menopause, particularly oestrogen deficiency, contribute to accelerated skin ageing through collagen degradation. By offering treatments that address both the hormonal imbalances and their aesthetic consequences, clinics can provide more comprehensive care and significantly benefit their clients.

‘In addition to facial treatments, many devices used for addressing facial ageing, such as radiofrequency or laser therapies, have been adapted to treat vaginal changes associated with menopause. Both areas experience similar issues; loss of mucosal and skin elasticity and thickness, and collagen degradation, making it possible to use these technologies to address concerns in both domains. Electromagnetic stimulation (such as Emsella), electrical stimulation (such as EmpowerRF (VTone)), PRP and exosomes can also provide relief from many of the symptoms of GSM, all non-surgically and with a short recovery time.

‘Menopause can be a sensitive topic, and the environment of an aesthetic clinic – often characterised by its relaxed, private setting – can facilitate open conversations about these issues. The extended treatment times and personalised care offered by these clinics provide an ideal opportunity to discuss menopause, its symptoms and available treatments. This not only helps build trust and loyalty with clients but also allows practitioners to address incontinence and sexual health concerns in a supportive manner. Having advanced devices available can also serve as a practical tool to initiate discussions and explore treatment options for these often-overlooked aspects of menopausal health.’

Dr Ginni Mansberg believes arming yourself, as an aesthetic practitioner, with knowledge about menopause is vital. ‘The women in your clinics are very likely to be at this stage of life. Understanding the hormonal swings and their impacts allow you to not only connect better but to be her superhero,’ she attests.

‘In addition, both perimenopause and menopause have enormous impacts on the skin. Understanding the role of oestrogen in the skin and the impacts of losing it will alter at least the topicals you suggest for your patients.’

‘To be honest, I think every health care practitioner needs this understanding – from rheumatologists who assess women with aches and pains to cardiologists who see the women with palpitations to neurologists who see women with escalating migraines or feeling like they have dementia. And don’t get me started on psychiatrists who continue to prescribe anti-depressants that are notoriously unhelpful at this stage of life instead of hormone therapy!

‘In the UK, many practitioners practice both menopause care and aesthetics. They do seem to go hand in hand.’

Chiza Westcarr, a menopause wellness coach and aesthetics educator, says the bread and butter of modern aesthetic practices is perimenopausal and menopausal women with ageing concerns.

‘There are many of us in aesthetics that do not make the connection. Here are just some of the changes that result in women flocking to aesthetic practices, desperate for help: collagen and elastin decline rapidly in the first 5 years; bone resorption occurs; dehydration and dryness increase; the skin thins; pigmentary changes become more noticeable; and wound healing slows as do cytokine and growth factor signalling, driving inflammation and contributing to the common skin-associated symptoms of menopause,’ she says.

Westcarr, who is hosting the Australian aesthetics industry’s first menopause symposium, Thriving Through Menopause, in February 2025, stresses that upskilling is the first step. ‘As aesthetic practitioners, we most definitely need to revise our approach, and to learn about menopausal skin and menopause as a whole, as this is not taught in any formal curriculum.

‘There are so many opportunities for practices to diversify and adapt their service offerings. We owe it to ourselves and to our patients.

‘Patients’ concerns are so much more than facial lines and wrinkles,’ she continues. ‘Every organ system has receptors for oestrogen; the hormonal decline causes changes to all aspects of the menopausal woman’s life – from brain fog and increased dementia risk to GSM and libido loss. By understanding the changes going on, we can not only provide a treatment journey but also resources and referrals to help her make informed choices.’

Charlotte Body is the Founder of Menopause in Aesthetics, a UK-based conference focusing on the synergy between menopause and aesthetics. She says that with the large majority of the demographic for aesthetic clinics being peri- or post-menopausal, coupled with many women reporting difficulty accessing support through their GPs, more and more aesthetic clinics are expanding their services beyond merely treating the skin- related impact of menopause.

‘Many women feel let down by their GPs when it comes to menopause, and aesthetic clinics are increasingly becoming the place they turn to,’ she says.

‘With the majority of patients visiting aesthetics clinics being in their 40s and 50s, practitioners are well placed to take the services they offer these women to the next level beyond merely addressing their lost collagen, lines and wrinkles.

‘We believe the future of aesthetic medicine isn’t anti-ageing; it’s agelessness and longevity, a holistic and 360-degree approach to menopause.’

The intersection of menopause and medical aesthetics presents a unique opportunity to provide women with better menopause care. Aesthetic practitioners can play a pivotal role in offering more than just skin-deep solutions and provide a more comprehensive approach in managing some of the broader impacts of menopause. AMP

Australian Senate Inquiry: Menopause care requires overhaul, upskilling

On November 6, 2023, the Australian Senate referred an inquiry into issues related to menopause and perimenopause to the Senate Community Affairs References Committee. Submissions closed 15 March 2024.

The Senate Inquiry will focus on the impact of menopause and perimenopause on:

  • economic consequences
  • physical health impacts and associated medical conditions
  • mental and emotional wellbeing, including mental health, self-esteem, and social support
  • cultural and societal factors influencing perceptions and attitudes toward menopause and perimenopause, including specifically considering culturally and linguistically diverse communities and women’s business in Aboriginal and Torres Strait Islander communities.

Another key area of the Inquiry is awareness among healthcare professionals and patients with symptoms of menopause and perimenopause and available treatments, including affordability and availability.

In its submission to the Senate Community Affairs References Committee, the RACGP says there is an urgent need for improved support and access to care for people experiencing menopause and perimenopause.

‘Upskilling of clinicians providing care for patients at midlife, concerning the indications for and prescribing of MHT, urgently needs to be addressed. Further education in recognising symptoms and signs but also a systematic evidence- based approach to management including non-drug therapy, MHT, and other management options is required,’ said RACGP President Dr Nicole Higgins.10 ‘Too many women are missing out on the care they need,’ she said.

‘One of the barriers to quality menopause care is patients having enough time to spend with their GP – current Medicare subsidies don’t adequately support people who need longer appointments. This care is complex, menopausal symptoms can have numerous physical and mental health impacts.’

Dr Higgins said another barrier to appropriate care is cost. ‘Many MHT products are not available on the PBS, making them too expensive for some patients,’ she told newsGP.

The AMA has also submitted its response and calls on the government to take action. The submission focused on six key issues:

  1. The central role GPs play in helping women to make informed decisions about their healthcare during menopause and perimenopause.
  2. Access challenges for women prescribed Menopausal Hormone Therapy (MHT) medicines.
  3. All women experiencing symptoms have the right to seek and receive the care they need.
  4. Menopause and the workplace.
  5. Funding boost for new research into menopause and perimenopause.
  6. Development of a National Menopause Framework.

These submissions to the Senate Inquiry join other organisations, including the Australian Psychological Society, Department of Health Victoria, Australian and New Zealand College of Anaesthetists and Women’s Wellbeing Association. The committee is tasked with reporting on the inquiry by September 17, 2024.

71% of Australian women unprepared for menopause

‘In Australia, while there is increasing awareness among women about common menopause symptoms like hot flushes and brain fog, understanding of more complex aspects – such as genitourinary syndrome of menopause (GSM), and the effects of oestrogen deficiency on the brain, cardiovascular system, gut and skin – is minimal,’ says Dr Judy Craig, medical director of Natural Looks Cosmetic Medicine in Perth and women’s health advocate. ‘Also, few women are aware that perimenopause may begin as early as 35 years and present with symptoms of anxiety, impaired cognition, depression and insomnia.

‘I have often raised the topic of menopause and in particular GSM with my patients during a cosmetic consultation, explaining that the changes that they are seeing on their face are also occurring in the intimate area. Many will then open up about symptoms of dryness, dyspareunia, incontinence and reduced sexual desire, intimacy and the impact on their relationship.

‘In my discussions, I find very few women are aware of the brain changes associated with changes in oestrogen and progesterone and the impact of this on memory, mood, anxiety, sleep quality, executive function and fatigue. These changes often undermine their work confidence, prompting many to contemplate or make career changes.

‘Few are also aware of the changes in the gut microbiome with menopause and its impact on weight and mood, or the latest results from studies on body-identical hormone therapy. Discussing these changes resonates with many women negotiating the menopausal changes.’

Dr Craig says while there is an increase in awareness of the need for menopausal hormonal therapy (MHT), amongst women, many women still leave their GP appointment without a prescription and continue to suffer.

‘Improving education and creating more open dialogues about menopause could help bridge these gaps, enhancing both understanding and support for women navigating this stage of life,’ she says.

Data from not-for-profit health fund HCF revealed more than 70% of Australian women aged 45 and over do not feel well informed or prepared for menopause.

The report, which surveyed more than 1,600 Australians also found:

  • The majority (92%) of Australiansfeels there are benefits to perimenopause and menopause being talked about more / being normalised
  • More than a third of Australian women aged over 45 are concerned that talking about menopause in the workplace could have a negative impact on the perception of their productivity
  • More than 50% of women sourced information from their GP/doctor about perimenopause/ menopause, while 40% turn to female friends.
  • Less than two in five (38%) women feel comfortable speaking to their partner about perimenopause and menopause.
Happy mature blonde lady

Practitioner’s Toolkit for the Management of the Menopause

Developed by the Women’s Health Research Program in the Monash University School of Public Health and Preventive Medicine, 2023, A Practitioner’s Toolkit for Managing Menopause guides health professionals around the world in assessing and treating for women at mid-life. It is endorsed by the International Menopause Society, Australasian Menopause Society, British Menopause Society, Endocrine Society of Australia and Jean Hailes for Women’s Health.

Published in Climacteric, the Toolkit has been updated and enhanced from the original 2014 Toolkit for practitioners with new advice and therapies based on a systematic review of the latest menopause research and best practice.

As well as outlining the latest general treatment guidelines, it offers bone health guidance as part of a menopause health assessment.

For example, clear guidelines about when menopause hormone therapies (MHT) might be needed to prevent bone loss and osteoporosis in asymptomatic women were lacking in 2014.

First author and Monash University Women’s Health Research Program head Professor Susan Davis, who also led development of the 2014 Toolkit, said the update included some new therapies but did not support MHT for cognitive symptoms or clinical depression.

‘For cognitive symptoms, clinical trials have not shown a benefit of MHT for cognitive function,’ Professor Davis said. ‘The most robust studies have shown it to be no better than placebo.

‘Regarding depression, menopause may cause symptoms such as low mood, anxiety, irritability, and mood swings, but clinical depression needs to be assessed and managed in its own right. Menopause might exacerbate underlying depression but should not be assumed to be the cause of clinical depression.’

Professor Davis said the advice was now much clearer around preventing bone loss and fracture. ‘To our knowledge this is the only document that provides guidance for using hormone therapy to prevent fracture,’ she said. ‘Other recommendations have been vague such as ‘can be used to prevent bone loss/fracture’ or ‘use to treat osteopenia’.’

Senior author Dr Rakib Islam, from the Monash University School of Public Health and Preventive Medicine Women’s Health Research Program, said the updates would make a difference for many. ‘The 2023 Practitioner’s Toolkit is the most up-to-date evidence-based practical guidance for health care providers to menopause care globally,’ he said.

Professor Davis said it was important for women to see their GP if they experienced troubling physical or mental health symptoms, and the update aimed to ensure GPs were well equipped.

‘We have updated this as part of an NHMRC Grant to upskill GPs and to embed the care algorithms into GP practice software in the MenoPROMPT study program, which aims to improve care for women who need it,’ she said. ‘This is a very important feature of this update.’

The paper’s authors said the recommendations needed to be applied in the context of local availability and the cost of investigations and drug therapies. ‘Most importantly, the Toolkit provides the full spectrum of available options and therefore can be used to support shared decision-making, and patient- informed care,’ they wrote.

Source: https://www.monash.edu/news/articles/landmark-menopause-toolkit-updated-to-improve-assessment-and-treatment

References:

1. Davis SR, Baber RJ. Treating menopause — MHT and beyond. Nat Rev Endocrinol 2022; 18: 490‐502, 2. Kim HK, Kang SY, Chung YJ, Kim JH, Kim MR. The Recent Review of the Genitourinary Syndrome of Menopause. J Menopausal Med. 2015 Aug;21(2):65-71, 3. Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. J Womens Health (Larchmt). 2019;28(2):117–134, 4. Huang S, Wang Z, Zheng D, Liu L. Anxiety disorder in menopausal women and the intervention efficacy of mindfulness-based stress reduction. Am J Transl Res. 2023 Mar 15;15(3):2016-2024, 5. Cordina-Duverger E, Truong T, Anger A, Sanchez M, Arveux P, Kerbrat P, Guénel P. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One. 2013 Nov 1;8(11):e78016. 6. Gilmer G, Hettinger ZR, Tuakli-Wosornu Y et al. Female aging: when translational models don’t translate. Nat Aging 3, 1500–1508 (2023), 7. https://hms.harvard.edu/news/how-gaps-scientific-data-lead-gaps-care-aging-womenunity, 8. https://www.abc.net.au/news/2022-12-19/medical-misogyny-womens-health-advisory-council/101780360, 9. Davis, SR, Magraith K. Advancing menopause care in Australia: barriers and opportunities. Med J Aust 2023; 218 (11): 500-502.10. https://www1.racgp.org.au/newsgp/clinical/senate-told-that-menopause-care-requires-overhaul

Previous articleVale Dr Alastair Carruthers: Pioneer of Botox for cosmetic use